Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 923

Sort by

Sort Order Select

Journal Articles

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood (2024) 143 (25): 2612–2626.

https://doi.org/10.1182/blood.2023022777

Published: 2024

Includes: Supplemental data

Journal Articles

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

Jooeun Bae, Shuichi Kitayama, Zach Herbert, Laurence Daheron, Keiji Kurata, Derin B. Keskin, Kenneth Livak, Shuqiang Li, Mubin Tarannum, Rizwan Romee, Mehmet Samur, Nikhil C. Munshi, Shin Kaneko, Jerome Ritz, Kenneth C. Anderson

Blood (2024) 143 (10): 895–911.

https://doi.org/10.1182/blood.2023020528

Published: 2024

Includes: Supplemental data

Journal Articles

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Maria Luisa Guerrera, Zachary R Hunter, Kris Richardson, Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna R Sarosiek, Catherine A. Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C Munshi, Steven P Treon, Xia Liu

Blood (2023) 142 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2023-190880

Published: 2023

Journal Articles

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

Mariateresa Fulciniti, Shuhui Deng, Sanika Dereibal, Vera Joy Weiler, Madhumouli Chatterjee, Jessica Ng Fong, Chandraditya Chakraborty, Rao Prabhala, Masood A. Shammas, Anil Aktas-Samur, Mehmet K. Samur, Annamaria Gulla, Kenneth C. Anderson, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2023-187374

Published: 2023

Journal Articles

A SNAP23-Dependent SNARE Complex Mediates Free Light Chain Secretion in AL Amyloidosis and Multiple Myeloma and Its Blockade Triggers a Terminal Unfolded Protein Response and Massive Apoptosis

Emre Karayol, Maria Moscvin, Tianzeng Chen, Peter G. Czarnecki, Annamaria Gulla, Kenneth C. Anderson, Giada Bianchi

Blood (2023) 142 (Supplement 1): 4662.

https://doi.org/10.1182/blood-2023-177714

Published: 2023

Journal Articles

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano, Claire Gao, Na Liu, Vanessa Favasuli, Marcello Turi, Pietro Folino, Mariateresa Fulciniti, Annamaria Gulla, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 640.

https://doi.org/10.1182/blood-2023-185523

Published: 2023

Journal Articles

Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients

Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Nickolas Tsakmaklis, Kris Richardson, Shirong Liu, Christopher J Patterson, Catherine A. Flynn, Kirsten Meid, Nikhil C Munshi, Kenneth C. Anderson, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon, Zachary R Hunter

Blood (2023) 142 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2023-190942

Published: 2023

Journal Articles

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Kris Richardson, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2023-190631

Published: 2023

Journal Articles

The Spop/BRD4/c-Myc Axis Modulates IMiDs Sensitivity in Multiple Myeloma

Lijie Xing, Jiye Liu, Kenneth Wen, Teru Hideshima, Kenneth C. Anderson, Zengjun Li

Blood (2023) 142 (Supplement 1): 4687.

https://doi.org/10.1182/blood-2023-187762

Published: 2023

Journal Articles

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Blood (2023) 142 (Supplement 1): 756.

https://doi.org/10.1182/blood-2023-190685

Published: 2023

Journal Articles

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Zachary R Hunter, Nickolas Tsakmaklis, Kris Richardson, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Ari M Melnick, Steven P Treon

Blood (2023) 142 (Supplement 1): 755.

https://doi.org/10.1182/blood-2023-190825

Published: 2023

Journal Articles

BCMA-Targeted Bortezomib Nanotherapy (BCMA-BTZ-Nps) Targets Tumor, Enhances Therapeutic Efficacy, Triggers Immunogenic Cell Death, Overcomes Drug Resistance, and Reduces Off-Target Toxicity in Multiple Myeloma (MM)

Debasmita Dutta, Jiye Liu, Kenneth Wen, Keiji Kurata, Mariateresa Fulciniti, Annamaria Gulla, Teru Hideshima, Kenneth C. Anderson

Blood (2023) 142 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2023-188237

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2023-177947

Published: 2023

Journal Articles

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Blood (2023) 142 (Supplement 1): 206.

https://doi.org/10.1182/blood-2023-177954

Published: 2023

Journal Articles

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

Wenqiang Yan, Xuehan Mao, David E. Mery, Yan Xu, Weiwei Sui, Shuhui Deng, Dehui Zou, John D Shaughnessy, Jr, Kenneth C. Anderson, Fenghuang Zhan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2023-182598

Published: 2023

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson

Blood (2023) 141 (21): 2599–2614.

https://doi.org/10.1182/blood.2022017897

Published: 2023

Includes: Supplemental data

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

NARROW

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

A SNAP23-Dependent SNARE Complex Mediates Free Light Chain Secretion in AL Amyloidosis and Multiple Myeloma and Its Blockade Triggers a Terminal Unfolded Protein Response and Massive Apoptosis

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

The Spop/BRD4/c-Myc Axis Modulates IMiDs Sensitivity in Multiple Myeloma

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

BCMA-Targeted Bortezomib Nanotherapy (BCMA-BTZ-Nps) Targets Tumor, Enhances Therapeutic Efficacy, Triggers Immunogenic Cell Death, Overcomes Drug Resistance, and Reduces Off-Target Toxicity in Multiple Myeloma (MM)

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only